NEW YORK, April 21, 2015 /PRNewswire/ -- Zofran lawsuits (http://www.zofranlawsuit2015.com/ ) that allege the anti-nausea medication may cause serious birth defects when it is used to treat expectant mothers during their first trimester of pregnancy continue to mount in courts around the U.S. According to court documents, one such lawsuit was filed on April 17th in U.S. District Court, District of Massachusetts, on behalf of a woman who was forced to terminate her pregnancy after her unborn child was diagnosed with severe fetal defects allegedly associated with Zofran. (Case No. 1:15-11627) A second complaint filed in the U.S. District Court, Eastern District of Texas, claims that pre-natal exposure to Zofran during the first trimester of pregnancy caused a child to suffer a number of congenital abnormalities, including a heart murmur, fluid on the brain, thickened arteries and multiple developmental delays. (Case No. DRU-1505-14)
"The allegations in these two complaints regarding the tactics GlaxoSmithKline used to market Zofran are strikingly similar to those included in a number of other birth defect lawsuits involving the mediation that have been filed in recent months. As our Firm is currently investigating similar allegations on behalf of a number of clients, we will continue to closely monitor developments in this growing litigation," Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now accepting inquiries from families whose child was allegedly born with a serious congenital abnormality due to pre-natal exposure to Zofran.
According to court documents, Zofran is an anti-nausea medication that has never been approved to treat nausea and vomiting related to pregnancy. The drug is currently classified by the U.S. Food & Drug Administration in Pregnancy Category B, which indicates its effects in pregnant women have not been well studied. Both of the Zofran lawsuits pending in Massachusetts and California allege that GlaxoSmithKline fraudulently marketed the medication as a safe and effective treatment for morning sickness, even though the company had never conducted studies to investigate its effects on pregnant women. The lawsuits further assert that Glaxo's own animal studies conducted in the 1980s indicated that Zofran could cross the placental barrier, and revealed evidence of toxicity, intrauterine deaths and malformations in offspring. Finally, the complaints claim that Glaxo has received at least 200 reports since 1992 of birth defects related to Zofran.
Court records indicate that these two new filings are among at least a half dozen Zofran lawsuits involving birth defect that are currently pending in U.S. courts. These cases include a filing made on April 1st in the U.S. District Court, Northern District of Alabama, which alleges Zofran was responsible for a number of congenital defects. (Case 2:15-cv-00544-JEO) On April 3rd, a Zofran lawsuit was filed in the U.S. District Court, District of Montana, which claims first-trimester Zofran use caused a child to be born with a cleft palate. (1:15-cv-00026-SPW-CSO)
Other Zofran lawsuits include a case filed on March 6th in California's Alameda Superior Court that alleges prenatal Zofran exposure caused a little boy to suffer a heart rhythm problem called supraventricular tachycardia. (Case No. RG15761042). A complaint filed on February 16th in U.S. District Court, District of Massachusetts, claims that Zofran caused a baby girl to be born with a number of congenital abnormalities, including heart defects. (Case 1:15-cv-10429) Two other children are alleged to have suffered Zofran-related heart defects in a case that was filed on February 12th in the U.S. District Court, Eastern District of Pennsylvania. (Case 2:15-cv-00709-PDC)
Children who allegedly suffered serious birth defects due to their mother's use of Zofran during the first trimester of pregnancy may be entitled to compensation from GlaxoSmithKline. To find out morehttp://www.zofranlawsuit2015.com/zofran-lawyer/ about available legal options, please visit Bernstein Liebhard LLP's website, or call the Firm directly at (888) 340-4807.
About Bernstein Liebhard LLP Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP 10 East 40th Street New York, New York 10016 (888) 340-4807